Projet NABBA (Horizon 2020, appel à projets 2014)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : CLOSED

Many therapeutic targets are shielded behind biological barriers, limiting the possibility to reach them with conventional drugs or diagnostic probes. Biological barriers are even more problematic for most biological pharmaceutics, such as recombinant proteins, antibodies and gene therapeutics. The most promising solution to this challenge is the use of nano-vehicles for specific targeting and delivery. The aim of NABBA is to form European early stage researchers (ESR) with cutting-edge scientific knowledge in the field of nanoparticles (NP) for biomedical application, able to cross biological barriers. For this aim the project will train ESRs, focusing on key aspects of nanobiotechnology: (i) design and chemical synthesis of different types of NPs, (ii) related techniques of detection and characterization, (iii) strategies of loading, targeting and delivery of drugs or diagnostic probes; (iv) proof of principle of pharmacological activity including pharmacokinetics and biodistribution. As a peculiar feature of NABBA, strong emphasis will be devoted to molecular mechanisms ruling biological barriers under physiological and pathological conditions, in order to develop novel nano-technological expedients for their crossing. Strong emphasis will be devoted to advanced chemistry issues, enabling new synthetic strategies either for NP assembly or functionalization. Different biological barriers will be addressed. ESRs will strongly benefit from a network of internationally recognized scientists in the field of chemistry, nanobiotechnology and nanomedicine, and the participation of companies with relevant interests and expertises in the field. The planned cooperation programs between Academia and Industries will allow the circulation of ESRs and this will give them the opportunity for to get acquainted with the most advanced research in the field, the most sophisticated technologies and the most advanced Industrial manufacturing platforms and innovative strategies.

Mots clés : nanoparticles, drug delivery, drug targeting, biological barriers

Participants :
- University of Santiago de Compostela (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 495745.92 €
- University of Milano-Bicocca (Italie) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 917551.36 €
- Novartis (Switzerland) (Suisse) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- PharmaMar (Spain) (Espagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Board of the Swiss Federal Institutes of Technology (Suisse) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Helmholtz Centre for Infection Research (Allemagne) — Partner, beneficiary, Recherche, subvention : 498432.96 €
- Enviroinvest kornyezetvedelmi es biotechnologiai zartkoruen mukodo reszvenytarasasag (Hongrie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 158418.82 €
- BioTalentum (Hungary) (Hongrie) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Centre national de la recherche scientifique (France) — Partner, beneficiary, Recherche, subvention : 525751.2 €
- Utrecht University (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 255374.28 €